A laboratory technician oversees the large-scale production and distribution of the Oxford University COVID-19 vaccine candidate AZD1222, which was performed on September 11, 2020 at the high-performance aseptic vial filling line in Catalant, Anagni, Italy. .
Vincenzo Pinto | AFP | Getty Images
LONDON: British pharmaceutical giant AstraZeneca will soon work with the Gamale Institute in Russia to investigate whether their two corona virus vaccine candidates can be successfully integrated.
This comes after the developers of the Sputnik v Kovid-19 vaccine approached AstraZeneca via Twitter last month to ask whether they should try to combine the two to increase the effectiveness of the vaccine.
“Combining different COVID-19 vaccines can help improve protection and / or improve vaccine permeability, so it’s important to explore different vaccine combinations to help make immunization programs more flexible, allowing vaccines to be selected by more physicians,” AstraZeneca said in a statement on Friday.
He added that the combination of vaccines could boost the immune system for a longer period of time.
AstraZeneca’s Kovid-19 vaccine, developed in collaboration with the University of Oxford, is one of several names seeking approval from medicine regulators amid hopes that a major immunization campaign could help end the pandemic.
To date, the corona virus has infected more than 69 million people worldwide, resulting in 1.58 million deaths, according to figures compiled by Johns Hopkins University.
“Combined evaluation of different types of COVID-19 vaccines can help unlock protective synergies, improve vaccine accessibility, and provide an additional approach to overcoming this deadly virus,” Astraseneka said.
The Russian Direct Investment Fund, Russia’s sovereign asset fund that funded the development of Sputnik V, said the clinical trials would begin later this month with its own combination of AstraZeneca’s vaccine.
“AstraZeneca’s decision to conduct clinical trials using one of the two vectors of Sputnik 5 to increase the effectiveness of its own vaccines is an important step in unifying efforts in the fight against pandemic,” said Kirill Dimitriev, CEO of Russian Direct Investment, in a statement.
“We welcome the beginning of this new phase of collaboration between vaccine manufacturers. We look forward to expanding this partnership in the future and launching joint production after the new vaccine demonstrates its effectiveness in clinical trials,” Dimitriev said.